Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

por Morley, Roland, Cardenas, Alison, Hawkins, Peter, Suzuki, Yasuyo, Paton, Virginia, Phan, See-Chun, Merchant, Mark, Hsu, Jessie, Yu, Wei, Xia, Qi, Koralek, Daniel, Luhn, Patricia, Aldairy, Wassim
Publicado 2015

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

por Desai, Jayesh, Deva, Sanjeev, Lee, Jong Seok, Lin, Chia-Chi, Yen, Chia-Jui, Chao, Yee, Keam, Bhumsuk, Jameson, Michael, Hou, Ming-Mo, Kang, Yoon-Koo, Markman, Ben, Lu, Chang-Hsien, Rau, Kun-Ming, Lee, Kyung-Hun, Horvath, Lisa, Friedlander, Michael, Hill, Andrew, Sandhu, Shahneen, Barlow, Paula, Wu, Chi-Yuan, Zhang, Yun, Liang, Liang, Wu, John, Paton, Virginia, Millward, Michael
Publicado 2020

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

por Boni, Valentina, Fidler, Mary J., Arkenau, Hendrik-Tobias, Spira, Alexander, Meric-Bernstam, Funda, Uboha, Nataliya, Sanborn, Rachel E., Sweis, Randy F., LoRusso, Patricia, Nagasaka, Misako, Garcia-Corbacho, Javier, Jalal, Shadia, Harding, James J., Kim, Stella K., Miedema, Iris H.C., Vugts, Danielle J., Huisman, Marc C., Zwezerijnen, Gerben J.C., van Dongen, Guus A.M.S., Menke van der Houven van Oordt, C. Willemien, Wang, Song, Dang, Tam, Zein, Ivan A., Vasiljeva, Olga, Lyman, Susan K., Paton, Virginia, Hannah, Alison, Liu, Joyce F.
Publicado 2022